Treatment options for psoriatic arthritis

Introduction: Recent years have witnessed tremendous development in the treatment of patients with psoriatic arthritis (PsA). Driven by greater understanding of the immunopathogenesis of disease, a number of novel treatment approaches have been developed and brought to the clinic. Additional therapies and treatment strategies are being explored. Areas covered: This paper discusses conventional and novel therapeutic options for treatment of PsA including agents under development. Novel treatment paradigms are also considered. Expert opinion: With newer therapies, in particular TNF inhibitors, treatment outcomes for patients with PsA have substantially improved. This has driven in advances in the approach to assessment of PsA, including composite measures of disease activity. Furthermore, novel treatment paradigms such as treat to target, early diagnosis and treatment, and consideration of tapering therapy among patients achieving low levels of disease activity are being actively explored. With these exciting developments, it is likely that outcomes for patients with PsA will continue to be improved in the foreseeable future.